+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Parkinson's Disease - Epidemiology Forecast to 2029

  • ID: 5310562
  • Report
  • March 2021
  • Region: Global
  • 31 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Parkinson's disease (PD) is a progressive disorder of the nervous system that affects movement by causing shaking, stiffness, and difficulty with walking, balance, and coordination (National Institute on Aging, 2017; Mayo Clinic, 2020). PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression (World Health Organization, 2020). PD is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, affecting 1-2% of individuals ages 65 years and older worldwide (Mhyre et al., 2012; Kowal et al., 2013).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for PD in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex, age, and HY clinical staging.

The following data describes epidemiology of PD. In the 7MM, the publisher's epidemiologists forecast an increase in the diagnosed prevalent cases of PD from 2,434,438 cases in 2019 to 2,999,337 cases in 2029, at an AGR of 2.32% over the forecast period. Men accounted for slightly more diagnosed prevalent cases of PD than women in the 7MM, and is one of the most common chronic progressive neurodegenerative disorders in the elderly population, as PD predominantly affects older adults. These trends are reflected in the publisher’s forecast for the diagnosed prevalent cases for the 7MM.

Scope
  • The Parkinson’s Disease (PD) Epidemiology Report provides an overview of the risk factors and global trends of PD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of PD are further segmented by Hoehn and Yahr (HY) clinical staging (stages I, II, III, IV, and V), and grouped into early (equivalent to HY clinical stages I-II), moderate-advanced (equivalent to HY clinical stages III-V), and advanced (equivalent to HY clinical stages IV-V).
  • The PD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy

The Parkinson’s Disease Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global PD market.
  • Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD therapeutics in each of the markets covered.
  • Understand magnitude of PD population by clinical staging.
Note: Product cover images may vary from those shown
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Parkinson’s Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for PD (2019-2029)
3.5.1 Diagnosed Prevalent Cases of PD
3.5.2 Sex-Specific Diagnosed Prevalent Cases of PD
3.5.3 Age-Specific Diagnosed Prevalent Cases of PD
3.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging
3.5.5 Diagnosed Prevalent Cases of PD by Type
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 COVID-19 Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact the Publisher
4.5 Disclaimer

List of Tables
  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities of PD
List of Figures
  • Figure 1: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019
  • Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
  • Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
  • Figure 5: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019
  • Figure 7: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
  • Figure 8: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll